European medicines agency activities related to api s
Download
1 / 41

european medicines agency activities related to api s - PowerPoint PPT Presentation


  • 461 Views
  • Uploaded on

European Medicines Agency Activities Related to API’s. WHO/EDQM/SFDA Conference Quality of Pharmaceutical Ingredients March 28, 2010 Guangxi Hotel, Beijing, China. Brendan Cuddy Scientific Administrator European Medicines Agency. Agenda. What is the European Medicines Agency?

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'european medicines agency activities related to api s' - albert


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
European medicines agency activities related to api s l.jpg

European Medicines Agency Activities Related to API’s

WHO/EDQM/SFDA Conference

Quality of Pharmaceutical Ingredients

March 28, 2010

Guangxi Hotel, Beijing, China

Brendan CuddyScientific Administrator European Medicines Agency


Slide2 l.jpg

Agenda

  • What is the European Medicines Agency?

  • API’s in the Marketing Authorisation Application

  • International Active Pharmaceutical Ingredients (API) Inspection Pilot Programme

  • Future developments

  • Summing Up

  • Questions and Discussion



The european union 493 million people 27 countries l.jpg
The European Union: 493 million people – 27 countries

Member states of the European Union

Candidate countries


Emea and the regulatory system in the eu l.jpg
EMEA and the Regulatory System in the EU

EMEA co-exists with over 40 National Competent authorities in the EU/EEA, forming an integrated network

A centralised procedure for Marketing Authorisation co-exists with procedures at national level (de-centralised procedure/mutual recognition procedure)

EMEA co-ordinates the existing scientific resources in Member States and provides an interface between all parties

EMEA works towards harmonisation of regulatory and technical requirements within the EU

EMEA scientific guidelines apply regardless as to the marketing authorisation procedure used


Emea and eu system l.jpg
EMEA and EU System

EU institutions:Commission, Parliament

and Council

42 National competent

authorities

4,000 European experts

Committee on

Advanced Therapies

(CAT)

Management Board

Committee for Orphan

Medicinal Products

(COMP)

Committee for

Medicinal Products for

Human Use

(CHMP)

EMEA

Paediatric Committee

(PDCO)

Pharmacovigilance

Committee ?

Committee for

Veterinary

Medicinal Products

(CVMP)

Committee for Herbal

Medicinal Products

(HMPC)

Industry Organisations

Patients and consumers

organisations



Key terms l.jpg

Marketing Authorisation

Manufacturing site(s) for

medicinal product

Manufacturing site(s) for

active substance(s)

Key Terms

Authorises the holder to place the medicinal product on the market

Sites located in EEA including importers must hold a manufacturing/importation authorisation (MIA)

Includes brokers who package, label and/or

Import active substances


Eu gmp inspection system l.jpg
EU GMP Inspection System

Collective implementation of Directives into national legislation

National Manufacturing Authorisations

Concept of Supervisory Authority

Mutual recognition of inspection outcomes.

All inspections “performed on behalf of the Community”

Collective adoption of identical guidelines

Harmonised practices

Compilation of Community Procedures

Joint audit programme

Regular meetings of the GMP/GDP Inspectors Working Group


Marketing authorisation l.jpg
Marketing Authorisation

Applications for marketing authorisation must specify the manufacturers of the active substance

This includes:

  • all stages involved in manufacture - from the first use of the active substance starting materials, through to the active substance used as a starting material by the dosage form manufacturer.

  • all companies/sites involved in manufacture of the active substance including those (re)packaging and (re)labelling

    It should be noted that importers (into EEA) of active substances are also “Manufacturers” of the active substance.


Declarations by the qualified person l.jpg
Declarations by the Qualified Person

Each application for marketing authorisation or relevant variation submission must be accompanied by a declaration signed by the QP of the manufacturing/importation authorisation holder(s) listed as manufacturer of the dosage form.

  • The declaration confirms that the active substance is manufactured in accordance with GMP

  • The declaration must cover all the manufacturing sites connected with the active substance


Qp declaration responsibilities l.jpg
QP Declaration: responsibilities

Active substance manufacturer

AUDIT

AUDIT

Batch release site and/or importer

Finished product manufacturer


Supervisory role of the competent authorities l.jpg
Supervisory role of the Competent Authorities

  • Inspections are carried out to verify that Manufacturing Authorisation holders are fulfilling their obligations

  • Member States are obliged by Community legislation to conduct inspections for this purpose and on behalf of all Member States.

  • In addition they may inspect active substance manufacturers. These inspections are mainly triggered by specific concerns.

  • Some Member States issue manufacturing authorisations to active substance manufacturers


Conditions for inspection of active substance manufacturers l.jpg
Conditions For Inspection Of Active Substance Manufacturers

No systematic routine inspection programme is required according to Community legislation

  • Where there are grounds for suspicion of non-compliance

    • At request of Member State, EMEA or Commission

  • To verify data submitted in application for a CEP

    • At request of EDQM

  • At the request of a manufacturer itself


  • Conditions for inspection of active substance manufacturers15 l.jpg
    Conditions For Inspection Of Active Substance Manufacturers

    Biologicals

    The quality of biological medicinal products are highly dependent on the manufacturing process and are usually characterised by it. GMP has therefore always been applied to the biological substance.

    Sterile active substances

    The sterilisation step in the production of a sterile active substance, where the active substance is to be incorporated aseptically in the manufacture of the medicinal product, is a manufacturing step of the medicinal product and has always been subject to GMP.

    Therefore subject to routine inspections


    Slide16 l.jpg

    Possible Triggers

    Possible Grounds for suspicion:

    • Unsatisfactory evidence of audit by manufacturer of medicinal product

    • Competent authority not satisfied with measures taken by medicinal product manufacturer

    • Concerns about distribution chain

    • Previous unsatisfactory inspection history

    • Concerns raised through CEP scheme

    • When disagreement on the conclusions of an inspection

    • Non compliance with specifications

    • Suspicions relating to authenticity of data



    Background of the project l.jpg
    Background of the project

    • Global supply chain for APIs / Global regulatory environment (ICH)

      Increasing demand for international collaboration on inspection work sharing on a risk-based approach

      Quality issues in 2008 for products with API manufactured outside EU (e.g. heparin)


    Justification of the project l.jpg
    Justification of the project

    • Better use of International inspectional resources allowing an increase inspectional coverage outside participating regions

      Better coordination/collaboration/information between authorities on sites of common interest can contribute to risk based inspection approaches and improve inspection efficiency.


    Justification of the project20 l.jpg
    Justification of the project

    • Information from the retrospective data :

    • Out of 85 sites which were inspected by more than 2 participants between 2005 and 2008 and for which the last inspection dates were known :

      • 8 sites were inspected during the same month

      • 7 sites were inspected within 3 month

      • 11 sites were inspected within 6 month

      • 20 sites were inspected within 12 month

      • 14 sites inspected within 2 years

      • 25 sites inspected within more than 2 years


    Organisation of the pilot program l.jpg
    Organisation of the Pilot Program

    Authorities performing significant number of inspections of APIs outside of their territories approached by European Medicines Agency end 2007

    • EU : France AFSSAPS, Germany ZLG, Ireland IMB, Italy AIFA, United Kingdom MHRA

    • MRA : Australian TGA

    • Council of Europe : EDQM

    • USA : US FDA

      All agreed to participate in a pilot phase to last for 18 months with recommendation for future action.


    Organisation of the pilot program22 l.jpg
    Organisation of the Pilot Program

    Always right to perform “own” inspections

    Use of a common GMP standard = ICH Q7

    All authorities to ensure if possible an agreed conclusion in case of joint inspection

    Each involved authority responsible for any follow-up actions (e.g. administrative or enforcement)

    Possible joint follow-up actions in case of GMP non- compliance


    Tools of the pilot program 1 l.jpg
    Tools of the Pilot Program (1)

    • Objectives developed into :

    • Update on a pilot project to collaborate on international GMP inspection activities

    • Rules of engagement and procedures for participating authorities (active pharmaceutical ingredients/active substances)

    • Organisation of bilateral and general teleconferences to built up the program and define a strategy for the sites of common interest


    Tools of the pilot program 2 l.jpg
    Tools of the Pilot Program (2)

    4. Confidentiality Agreements signed between the participating authorities to allow sharing of inspection plans

    5. Template spreadsheet for exchange of inspection planning's, retrospective and prospective, defined.

    6. Creation of a master list of common sites

    • http://www.ema.europa.eu/Inspections


    Sites for cooperation in 2009 2010 l.jpg
    Sites for cooperation in 2009/2010

    • 920 sites (entries) identified and shared

    • 350 sites not shared

    • Total of : 213 common sites

    • sites common to 2 participants : 118 sites

    • sites common to 3 participants : 57 sites

    • sites common to 4 participants : 32 sites

    • sites common to 5 participants : 6


    Geographic distribution of the api manufacturers l.jpg
    Geographic distribution of the API manufacturers

    • China : 104 sites from which 43 are not shared

      • 39 shared by 2

      • 14 shared by 3

      • 6 shared by 4

      • 2 shared by 5

      • 58 % of the sites in China are shared


    Activities within the pilot program l.jpg
    Activities within the Pilot Program

    • Main activities to be developed within the program based on the sharing of inspections planning:

      Sharing of inspection reports of passed inspections

      Sharing of inspection reports of planned inspections with or without scope extension

      Joint inspection with or without scope extension.


    Scenario a inspection report sharing passed or future inspection l.jpg
    Scenario a: inspection report sharingpassed or future inspection

    API manufacturer in third country

    API 1

    API 1 is used in medicinal products in EU (CAP) & US.

    EU/US both interested in the inspection and agree to delegate the inspection to one of them and to share the inspection report.

    Possible for the same scope or overall GMP compliance


    Scenario b sharing of inspection reports of planned inspection s with extension of the scope l.jpg
    Scenario b: sharingof inspectionreports of plannedinspections with extension of the scope

    API manufacturer in third country

    API 1

    API 2

    API 1 is used in medicinal products marketed in EU (CAP) and a CEP was granted by EDQM.

    API 2 is used in a product in Australia

    EDQM/European Medicines Agency/TGA are interested in the inspection and agree to delegate the inspection to one of them, extending the scope of the inspection to cover API 1/2 and to share the inspection report.


    Scenario c joint inspection l.jpg
    Scenario c: joint inspection

    API manufacturer in third country

    API 1

    API 2

    API 3

    API 1 and API 2 are used in medicinal products marketed in EU(CAP) , in US and in Australia.

    API 2 and API 3 were granted a CEP by EDQM.

    EDQM/European Medicines Agency/FDA/TGA are interested in the inspection and agree to organise a joint inspection done by two of them, covering API 1/2/3 and share the inspection report with all.


    Joint inspections feb 2010 l.jpg
    Joint inspections Feb. 2010

    EDQM , 5 joint inspections :

    3 TGA - 1 MHRA - 1 European Medicines Agency

    European Medicines Agency, 2 joint inspections

    1 FDA - 1 EDQM

    FDA, 2 joint inspections

    1 European Medicines Agency – 1 TGA

    TGA, 5 joint inspections

    3 EDQM - 1 FDA - 1 MHRA


    Key performance indicators l.jpg
    Key Performance Indicators

    Increased transparency and visibility of participants inspections planning

    Decrease in “duplicate inspections” i.e inspections of the same product or sites carried out by more than one authority within a similar time period

    Increase in number of inspections of value to more than one authority performed

    Positive assessment of the deliverables


    N ext steps l.jpg
    Next steps

    Regular teleconferences and e-mail exchanges for the development of the program.

    Improving the knowledge of each other’s organisation and constraints

    Improve the exchange of information by gathering and sharing more data on site inspections planning (all sites, APIs inspections schedules and reporting tools (e.g. feedback forms)

    Reliance on each other’s inspections will increase resource available to cover more sites.


    Future developments l.jpg
    Future Developments

    Legal proposal to combat counterfeit medicines

    Pedigree of API Supply Chain Security


    Ec envisages a combination of tightened requirements in the api area l.jpg
    EC envisages a combination of tightened requirements in the API area

    Notification requirements

    Tightened GMP standards

    Enhanced inspections


    Slide36 l.jpg

    Notification requirements API area

    Mandatory notification for manufacturers/importers of APIs

    Present

    Proposed

    • API manufacture

    • & import to mandatory notification procedure

    • Information on notified parties

    • available in a Community database

    • (EudraGMP database extension)

    • legal framework for APIs only on

    • manufacture

      • activities of distributors, traders,

      • agents and brokers outside

      • scope of Community legislation

        • should be subject to the relevant GMP


    Slide37 l.jpg

    Audit and enforceability of GMP API area

    Enhancing audit and enforceability of GMP

    Present

    Proposed

    • Make regular audits of API suppliers on GMP compliance mandatory

      • auditors sufficiently qualified

      • third-party audits by accredited companies

    • Control of APIs via discriminating analytical techniques

    • Principles of GMP for APIs into a legal act of Community law

    • obligation of the MIA holder to source from GMP compliant API manufacturers

    • in practice auditing by the MIA holder (EU FP manufacturer or importer)

    • FP manufacturers test APIs supplied to them

      • other sites / other processes as declared


    Slide38 l.jpg

    API GMP inspections API area

    Enhancing API GMP inspections

    Present

    Proposed

    • inspections by competent authorities restricted to suspected non-compliance with GMP

    • Particular concerns for manufacturing in third countries (TC):

      • GMP not equivalent to EU

      • inspection and control mechanisms insufficient

    • Need to continue cooperation with TC

      • bilateral arrangements

      • international synergies in performing inspections

    • Legal basis for any GMP API inspection

    • competent authorities (EU inspectorates) shall carry out API inspections if suspicion of non-compliance with GMP

    • The competent authority shall carry out repeated inspections in the exporting country (TC) if

      • GMP in TC not at least equivalent to EU

      • mechanisms for supervision and inspections not at least equivalent to EC


    Pedigree of api supply chain l.jpg
    Pedigree of API Supply Chain API area

    Proposal for amendment of GMP Guide to introduce a pedigree concept for API’s.

    Proposal still very much in draft form

    Work anticipated to continue on the proposal throughout 2010.


    To sum up l.jpg
    To sum up API area

    • Overview of API’s in Marketing Authorisation

    • Inspections of active substance manufacturers

    • International Pilot Programme

    • New initiatives e.g EC proposals


    Slide41 l.jpg

    Questions and Discussion API area

    European Medicines Agency

    7, Westferry Circus

    Canary Wharf

    London E14 4HB

    United Kingdom

    Tel: +44 (0) 20 7418 8400

    Fax: +44 (0) 20 7418 8416

    www.ema.europa.eu/Inspections/index.html

    [email protected]


    ad